Lutetium-177 (Lu-177) Market Growth Analysis, Market Dynamics, Key Players and Innovations, Outlook and Forecast 2025-2032
As of 2023, the global Lutetium-177 (Lu-177) market was valued at approximately USD 1,564 million. With significant growth anticipated due to increasing adoption in oncology and targeted radionuclide therapy, the market is projected to reach USD 6,376.28 million by 2032. This reflects a strong compound annual growth rate (CAGR) of 16.90% over the forecast period.
Get free sample of this report at : https://www.intelmarketresearch.com/Lutetium-177-Market-888
Lutetium-177 (Lu-177) is a radioactive isotope derived
from lutetium, a rare-earth element with the atomic number 71. Known for its
dual emission of beta particles and gamma rays, Lu-177 is primarily used in
targeted radionuclide therapy. Its therapeutic applications are centered around
its capability to deliver precise radiation doses to cancer cells while
minimizing exposure to healthy tissues. Lu-177 is most commonly utilized in
treating cancers such as neuroendocrine tumors and advanced prostate cancer. In
medical treatments, Lu-177 is often paired with biological targeting molecules,
like peptides or antibodies, to selectively bind to cancer cell receptors. A
prominent example is Lu-177 DOTATATE for neuroendocrine tumors and Lu-177 PSMA
for prostate cancer. These radiopharmaceuticals offer superior therapeutic
efficacy and lower systemic toxicity, positioning Lu-177 as a vital component
in the growing field of nuclear medicine and personalized oncology.
Market Size
North America alone contributed an estimated USD 534.15
million in 2023 and is forecasted to grow at a CAGR of 14.49% through 2032.
This region's growth is driven by advanced healthcare infrastructure, increased
cancer prevalence, and supportive regulatory frameworks for nuclear medicine.
Historically, the Lutetium-177 market has experienced a
surge due to the expanding applications of precision medicine and the
integration of radiopharmaceuticals in routine clinical practice. With
continued investment in research and favorable clinical outcomes, the Lu-177
market has evolved from a niche sector to a mainstream solution in cancer
therapeutics.
March 2025: The U.S. FDA expanded the indication for
Novartis’ Pluvicto (Lu-177 vipivotide tetraxetan) to include earlier-stage
metastatic castration-resistant prostate cancer (mCRPC), potentially tripling
the eligible patient population.
Market Dynamics (Drivers, Restraints, Opportunities, and
Challenges)
Drivers
Rising Demand for Targeted Cancer Therapies
The growing need for specific and targeted cancer
treatments, particularly for diseases like gastroenteropancreatic
neuroendocrine tumors (GEP-NETs) and metastatic castration-resistant prostate
cancer (mCRPC), is the main factor propelling the Lu-177 market. Lu-177
radiopharmaceuticals are a preferred choice in advanced oncology care because
of their remarkable clinical efficacy and lower side effect rates when compared
to conventional therapies.
According to Wordl Health Organization, in 2022, there
were an estimated 20 million new cancer cases and 9.7 million deaths. The
estimated number of people who were alive within 5 years following a cancer
diagnosis was 53.5 million. About 1 in 5 people develop cancer in their
lifetime, approximately 1 in 9 men and 1 in 12 women die from the disease.Over
35 million new cancer cases are predicted in 2050, a 77% increase from the
estimated 20 million cases in 2022
Restraints
Rising Demand for Targeted Cancer Therapies
Due to the highly specialized infrastructure required for
isotope generation and radiolabeling, as well as the limited global production
capacity, the Lu-177 market is constrained despite rising demand. Reactor-based
techniques are used to produce no-carrier-added (NCA) Lu-177, necessitating
close regulatory supervision and collaboration with nuclear facilities.
By 2024, only a small number of facilities worldwide, primarily in North
America, Europe, and Australia, will be able to produce medical-grade NCA Lu-177.
This will result in long lead times and supply bottlenecks for manufacturers of
radiopharmaceuticals.
April 2024: The FDA approved Lutathera (Lu-177
dotatate) for pediatric patients aged 12 and older with somatostatin
receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs),
marking the first radiopharmaceutical approval for this age group.
Opportunities
Expansion of Theranostics and Emerging Markets
The market for Lu-177 has a significant opportunity due
to theranostics, which combines therapy and diagnostics. Clinical success rates
are rising as a result of the growing use of companion diagnostics with PET
imaging, which enables more efficient patient selection and treatment planning.
Furthermore, new growth areas are being opened up by the expansion of nuclear
medicine infrastructure in Latin America and Asia-Pacific.
Include a few figures.
Nations such as Brazil and India are funding their own nuclear medicine
facilities and isotope production facilities. In 2023, India's BARC started
producing Lu-177 domestically, lowering reliance on imports and creating
opportunities for the region.
Challenges
Regulatory Hurdles and Safety Compliance
Strict regulatory frameworks controlling radioactive
substances, including patient safety, storage, and transportation, must be
negotiated by the Lu-177 market. Timely access to therapies may be hampered by
approval delays, restrictions on the shipment of isotopes across international
borders, and adherence to changing pharmacovigilance regulations.
Regional Analysis
Due to its robust healthcare system, high volume of
nuclear medicine procedures, and early adoption of radiotheranostics, North
America leads the global market for Lu-177. With FDA approvals for Lu-177-based
treatments like Pluvicto (2022) and Lutathera (2018) promoting clinical
adoption, the U.S. is a crucial hub.
According to National Center for Health
Statistics In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths
are projected to occur in the United States. The cancer mortality rate
continued to decline through 2022, averting nearly 4.5 million deaths
The second-largest market is Europe, which has robust
public healthcare systems and cutting-edge nuclear research facilities. France,
the Netherlands, and Germany are among the major producers and users of Lu-177.
Clinical trials and cross-border distribution are made easier by EU regulatory
harmonization.Two significant European companies investing in the large-scale
production of Lu-177 are Eckert & Ziegler and Isotope Technologies Munich
SE. With more than 50 nuclear medicine facilities providing Lu-177 treatments
as of 2024, Europe is also a leader in neuroendocrine tumor (NET)
therapy.Rising cancer rates, growing nuclear medicine infrastructure, and
government support are driving the fastest-growing regional market in
Asia-Pacific. To lessen their dependency on imports, nations like Australia,
South Korea, China, and India are increasing their domestic production of
isotopes. China's CNNC is making significant investments in facilities for the
production of radiopharmaceuticals. Through public-private partnerships, Japan
and Australia are increasing clinical access to theranostics based on Lu-177.
Competitor Analysis (in brief)
Major players in the Lu-177 market include:
- Advanced
Accelerator Applications (Novartis): A global leader with strong
product pipelines and wide distribution networks.
- Eckert
& Ziegler Strahlen: Known for producing high-purity Lu-177,
especially the NCA variant.
- SHINE
Technologies: Focused on scalable and environmentally friendly
isotope production.
- ANSTO: An
Australian entity playing a key role in the Asia-Pacific supply chain.
- NTP
Radioisotopes: A significant producer in the African continent, with
global distribution capacity.
These companies are continuously engaged in mergers,
product launches, and R&D investments to enhance their market positioning.
To support the development of treatments for prostate
cancer and neuroendocrine tumors, SHINE Technologies and Nucleus RadioPharma
signed a long-term supply agreement for Lu-177.
Global Lutetium-177 (Lu-177) Market: Market Segmentation
Analysis
This report provides a deep insight into the global
Lutetium-177 (Lu-177) market, covering all its essential aspects. This ranges
from a macro overview of the market to micro details of the market size,
competitive landscape, development trend, niche market, key market drivers and
challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition
within the industries and strategies for the competitive environment to enhance
the potential profit. Furthermore, it provides a simple framework for
evaluating and assessing the position of the business organization. The report
structure also focuses on the competitive landscape of the Global Lutetium-177
(Lu-177) Market. This report introduces in detail the market share, market
performance, product situation, operation situation, etc., of the main players,
which helps the readers in the industry to identify the main competitors and
deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry
players, investors, researchers, consultants, business strategists, and all
those who have any kind of stake or are planning to foray into the Lutetium-177
(Lu-177) market in any manner.
May 2025, To ensure a consistent supply of isotopes
for Radiopharm's clinical programs, ITM Isotope Technologies Munich SE and
Radiopharm Theranostics signed a supply agreement for non-carrier-added Lu-177.
March 2025, Curium expanded its PET imaging
footprint and increased its capacity to produce Lu-177 after completing the
acquisition of Monrol.
May 2024, Mariana Oncology was acquired by Novartis
for $1 billion, bolstering its pipeline of radiopharmaceuticals, including
treatments based on Lu-177.
November 2023, In order to support the development
of treatments for prostate cancer and neuroendocrine tumors, SHINE Technologies
and Nucleus RadioPharma signed a long-term supply agreement for Lu-177.
Market Segmentation (by Type) :
- Carrier-Free
Lutetium-177
- Carrier-Added
Lutetium-177
Market Segmentation (by Application) :
- Prostate
Cancer
- Neuroendocrine
Tumors (NETs)
- Bone
Metastases
- Non-Hodgkin's
Lymphoma
- Clinical
Research & Trials
Market Segmentation (by End User) :
- Hospitals
- Cancer
Research Institutes
- Research
Institutes & Academic Centers
- Pharmaceutical
& Biotechnology Companies
- Academic
& Research Centers
Key Company :
- Advanced
Accelerator Applications (Novartis)
- Eckert
& Ziegler Strahlen
- SHINE
Technologies
- ANSTO
- NTP
Radioisotopes
Geographic Segmentation :
- North
America (USA, Canada, Mexico)
- Europe
(Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific
(China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South
America (Brazil, Argentina, Columbia, Rest of South America)
- The
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa,
Rest of MEA)
FAQ :
▶ What is the current market size of the Lutetium-177
(Lu-177) market?
As of 2023, the market is valued at approximately USD
1,564 million, with projections to reach over USD 6.3 billion by 2032.
▶ Which are the key companies operating in the
Lutetium-177 (Lu-177) market?
Major players include Advanced Accelerator
Applications (Novartis), Eckert & Ziegler, SHINE Technologies, ANSTO, and
NTP Radioisotopes.
▶ What are the key growth drivers in the Lutetium-177
(Lu-177) market?
Growth is primarily driven by rising cancer prevalence,
the efficacy of targeted radionuclide therapy, and supportive regulatory
frameworks.
▶ Which regions dominate the Lutetium-177 (Lu-177)
market?
North America and Europe currently lead, while
Asia-Pacific is projected to see the fastest growth.
▶ What are the emerging trends in the Lutetium-177
(Lu-177) market?
Key trends include expanding indications, improved
isotope production technologies, and increasing collaborations in emerging
markets.
Comments
Post a Comment